Overview

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Status:
Recruiting
Trial end date:
2022-06-28
Target enrollment:
Participant gender:
Summary
This is a first in human study to assess the safety, tolerability, PK, PD and preliminary efficacy of CC-94676 in men with progressive metastatic castration-resistant prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Celgene